*UBS cuts Idenix price target to $9 from $10. *UBS raises Celgene price target to $82 from $80. Reuters Station users, click. 1568.
*Credit Suisse cuts Idenix Pharmaceuticals Inc to underperform from.
Bristol-Myers Squibb suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue — a major blow to the company’s research pipeline that is also likely to rejigger the way Wall Street views other companies’ efforts to develop an all-oral therapy against the viral liver disease.
Stocks wobbled out of the gate Wednesday, with traders hesitant to make any strong commitments head of the afternoon Federal Reserve policy decision.
U.S. stock index futures pointed to a mixed open on Wall Street on Wednesday as investors turned their attention away from the G20 Summit and the euro zone crisis and concentrated instead on domestic concerns.
Check out which companies are making headlines after the bell Tuesday:
Idenix Pharmaceuticals didn’t perform after a bullish trade last month, but investors are trying again.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
There is a great chance that Sirius XM Radio’s stock will hit $1.65 within the next several sessions — in other words, this is bound to get worse before it gets better.
Here’s a look at several under-$10 stocks that look poised to potentially trade higher from current levels.
Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.
After a hot streak, biotech stocks lose value as clinical trials fail.
Hedge funds that manage more than $100 million are required to disclose their equity holdings, options and convertible debt on a Form 13F. TheStreet.com examines Baupost Group's holdings.
Insight on the FDA clearing Idenix to resume study of its advanced experimental hepatitis C drug, with Ronald Renaud, Idenix president/CEO.
Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.
As the JPMorgan Health Care conference kicks off this week, one question remains for investors in the biotech space. What’s the next takeover target as large drug makers look to build out their pipeline?
Hedge funds peeled back the curtain this week to reveal a bit about what biotech stocks they were buying and selling during the second quarter.
So far this year, the Russell 2000 index of small-cap companies continues to outperform the Dow, and the S&P 500. While most of these companies average only a $1 billion dollar market capitalization, some of their returns are proving resilient to an economic slowdown.